WO2017154912A1 - Composition cosmétique - Google Patents

Composition cosmétique Download PDF

Info

Publication number
WO2017154912A1
WO2017154912A1 PCT/JP2017/009027 JP2017009027W WO2017154912A1 WO 2017154912 A1 WO2017154912 A1 WO 2017154912A1 JP 2017009027 W JP2017009027 W JP 2017009027W WO 2017154912 A1 WO2017154912 A1 WO 2017154912A1
Authority
WO
WIPO (PCT)
Prior art keywords
cosmetic composition
skin
photoaging
fulvic acid
acid
Prior art date
Application number
PCT/JP2017/009027
Other languages
English (en)
Japanese (ja)
Inventor
金川シーラ
Original Assignee
株式会社スタイルアンドバリュージャパン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社スタイルアンドバリュージャパン filed Critical 株式会社スタイルアンドバリュージャパン
Publication of WO2017154912A1 publication Critical patent/WO2017154912A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to a cosmetic composition, and more particularly to a cosmetic composition for preventing or improving the photoaging phenomenon of skin.
  • the skin is mainly divided into epidermis, dermis and subcutaneous tissue.
  • the dermis is located under the basal layer of the epidermis and is a layer having a thickness of 2 mm consisting of a protein fiber made of collagen and elastin and a substrate.
  • Collagen in the dermis accounts for 70-80% (dry weight) of the dermal extracellular matrix, more than 90% is type I collagen.
  • Collagen gives skin elasticity and supports elastin.
  • Elastin is about 2%, but gives skin elasticity.
  • Substrates that fill between protein fibers are extracellular matrix components such as proteoglycan and hyaluronic acid.
  • Non-Patent Documents 1 and 3 In addition, elastic fiber elastin occupying 2 to 4% (dry weight) of the dermal extracellular matrix has been observed to undergo changes such as loss of elastic fiber network structure and increase in amorphous elastin when exposed to ultraviolet light.
  • Ultraviolet rays include short wavelength ultraviolet rays (UVC) of 190 to 290 nm, medium wavelength ultraviolet rays (UVB) of 290 to 320 nm, and long wavelength ultraviolet rays (UVA) of 320 to 400 nm.
  • UVC short wavelength ultraviolet rays
  • UVB medium wavelength ultraviolet rays
  • UVA long wavelength ultraviolet rays
  • UVC short wavelength ultraviolet rays
  • UVB medium wavelength ultraviolet rays
  • UVA long wavelength ultraviolet rays
  • UVA exposure reduces the ability of fibroblasts to synthesize collagen (Non-patent Document 6), and mRNA of matrix metalloproteinase (Matrix meta11 protease, MMP), an extracellular matrix component degrading enzyme It has been reported to promote expression. As described above, it is considered that the photoaging phenomenon increases the activity and expression level of MMP due to long-term exposure to ultraviolet rays and the like, and causes collapse and decrease of collagen as an extracellular matrix component.
  • MMP matrix metalloproteinase
  • the activation of MMP-1 collagenase by UV exposure and the increase in production amount contribute to the photoaging phenomenon. Therefore, the inventor has produced MMP-1 whose activity is increased by UV exposure. We thought that searching for substances to suppress is effective in preventing structural changes in the dermal matrix due to photoaging. Therefore, the present inventor searched for a substance having an inhibitory effect on MMP-1 production using a three-dimensional skin model that is close to the behavior in skin tissue.
  • Humus is a polymer formed mainly by the decomposition of carbohydrates and proteins in plant residues and microbial remains in soil by microorganisms and condensation of the degradation products. Humus contains amorphous polymers such as fulvic acid and humic acid. Humic acid is a red-brown to black-brown amorphous polymeric organic acid that is soluble in alkali and insoluble in acid. On the other hand, fulvic acid is an amorphous high molecular organic acid soluble in alkali and acid.
  • an object of the present invention is to search for substances that comprehensively prevent photoaging of the skin by improving the cell survival rate in addition to suppressing MMP-1 production upon exposure to ultraviolet rays, and provide its use. There is.
  • the present inventor has found that a humic extract containing fulvic acid defined by specific wave number (wavelength) infrared absorption has not only an MMP-1 production inhibitory effect but also a cell viability. Found to improve. Based on this finding, the present inventor has solved the above problems. That is, the present invention relates to a humus extract containing fulvic acid having infrared absorption peaks at wave numbers 3362, 2875, 1675, 1359, 1360, 1200, 1047 and 835 cm ⁇ 1 in an infrared absorption spectrum in the FT-IR method, and a cosmetic.
  • a cosmetic composition comprising a pharmaceutically, dermatological and / or pharmaceutically acceptable additive or food additive is provided.
  • Fulvic acid a kind of humic substance, has a wide variety of molecular structures and substituents. Fulvic acid characterized by the infrared absorption spectrum specified in the present invention suppresses MMP-1 production upon exposure to ultraviolet light. Along with the effect, it has a function of improving the cell viability of the skin by suppressing the generation of active oxygen or quickly removing the generated active oxygen.
  • the humus extract contains fulvic acid having an infrared absorption spectrum shown in FIG.
  • the humus extract does not have a naphthalene ring structure.
  • the average molecular weight of fulvic acid in the humus extract is preferably smaller than 4,000.
  • the cosmetic composition is preferably used to prevent photoaging of the skin.
  • the prevention of the photoaging is particularly characterized by suppressing the production of MMP-1 and improving the cell viability of skin cells.
  • the cosmetic composition of the present invention is preferably for transdermal administration.
  • the form of the cosmetic composition for transdermal administration is, for example, a liquid, a liquid, an emulsion, an emulsion, an emulsion, a cream or a powder.
  • the cosmetic composition of the present invention is also preferably for oral administration.
  • the form of the cosmetic composition for oral administration is, for example, powder, granule, capsule, pill, tablet, chewable tablet, drop, liquid preparation or syrup.
  • the cosmetic composition of the present invention containing a humus extract containing fulvic acid defined by a specific infrared absorption wavelength, the production of MMP-1 upon exposure to ultraviolet rays is suppressed, and the survival rate of skin cells is reduced. Increase significantly.
  • the cosmetic composition of the present invention is effective in preventing or improving the photoaging phenomenon of skin caused by ultraviolet irradiation, such as skin talmi, wrinkles, kojiwa, bears, blemishes, and rough skin.
  • FIG. 2 is a diagram of an FT-IR absorption spectrum based on an ATR method of a fulvic acid fraction of a humus extract (product name: Humicle (registered trademark)) used in Example 1.
  • FIG. 4 is an FT-IR absorption spectrum diagram based on the ATR method for fulvic acid and humic acid extracted and purified from terraced forest soil shown in Comparative Example 1.
  • 2 is a three-dimensional fluorescence spectrum diagram of a 4% aqueous solution of humus extract used in Example 1.
  • FIG. 1 is a diagram of an FT-IR absorption spectrum based on an ATR method of a fulvic acid fraction of a humus extract (product name: Humicle (registered trademark)) used in Example 1.
  • FIG. 4 is an FT-IR absorption spectrum diagram based on the ATR method for fulvic acid and humic acid extracted and purified from terraced forest soil shown in Comparative Example 1.
  • 2 is a three-dimensional fluorescence spectrum
  • FIG. 3 is a three-dimensional fluorescence spectrum diagram of an aqueous solution (concentration 10 ⁇ g / mL) of a terraced fulvic acid and an aqueous solution (concentration 10 ⁇ g / mL) of a terraced humic acid used in Comparative Example 1.
  • FIG. 10 is a three-dimensional fluorescence spectrum diagram of an aqueous solution (concentration 10 ⁇ g / mL) of a terraced fulvic acid and an aqueous solution (concentration 10 ⁇ g / mL) of a terraced humic acid used in Comparative Example 1.
  • a humus extract having the infrared absorption peak described above A humus extract will not ask
  • the humus extract having this infrared absorption spectrum can be obtained from, for example, a humic shale that is an ancient plant deposition layer (shale layer) in Emery County, Utah, USA. Humic shale is a fertile soil containing many nutrients from about 7,000 to 127 million years ago, and remains as organic matter without being transformed into oil or coal.
  • the humus contained in the formed deposited layer contains as a main component an organic polymer such as fulvic acid and humic acid, and contains 70 or more trace amounts of minerals.
  • the humus extract is extracted into water by mixing the humus with water (for example, distilled water, ion exchange water, reverse osmotic pressure water, etc.). At that time, the humus is usually mixed at a ratio of 5 to 35 parts by weight, preferably 15 to 25 parts by weight, particularly preferably 17 to 18 parts by weight with respect to 100 parts by weight of water. The mixture is left at room temperature, usually for 24 to 96 hours, preferably 48 to 72 hours. During the standing, the mixture may be appropriately stirred. Next, the supernatant or filtrate of the above mixture is used as a humus extract. The pH of the liquid humus extract is usually 3.0. This liquid humus extract may be dried to a powder.
  • water for example, distilled water, ion exchange water, reverse osmotic pressure water, etc.
  • the humus is usually mixed at a ratio of 5 to 35 parts by weight, preferably 15 to 25 parts by weight, particularly preferably 17 to 18 parts by weight with respect to 100 parts by
  • the average molecular weight of fulvic acid in the humus extract is usually less than 4,000, preferably not more than 3,500, particularly preferably not more than 3,000, more preferably 3,000 to 1, 000.
  • the humus extract may be commercially available, and is available in Japan under the product name “Humicle (registered trademark) HC fulvic acid powder” from, for example, Style and Value Japan. Table 1 shows the component analysis results (content in the sample wet weight).
  • Fulvic acid was fractionated by extracting the fumaric alkali (0.1N sodium hydroxide) and acid (hydrochloric acid, pH 2) soluble components.
  • the physical property test method and analysis results of the fumicle or fulvic acid fraction are shown below.
  • FIG. 3 shows a three-dimensional excitation-fluorescence spectrum (measuring apparatus JASCO FP-8200) of a 4% aqueous solution of Humicle.
  • fulvic acid and humic acid extracted and refined from Danto forest soil in Aichi Prefecture both are distributed as “Standard Material of the Japanese Humic Society” by the Japanese Humic Society, respectively.
  • the GPC-UV / TC analysis method separates dissolved organic substances in water at a high speed according to the size of the molecule and the degree of exclusion, and separates the separated dissolved molecules into a UV detector and a TC detector (Total Carbon). (Analyzer) is a monitoring method.
  • GPC-TC device GPC: Shodex GPC SYSTEM 21 Separation column TOSO HW-50S Eluent 30 mM Na 2 HPO 4 UV absorption (220 nm) detector: GL7450 (manufactured by GL Sciences) TC detector: LCT-100 (manufactured by Toray Engineering) was used to measure the molecular weights of the fumicle and the fulvic acid from Dando.
  • the peak position of Danto fulvic acid was 51 minutes, whereas it was 54 minutes for the 4% humicule solution.
  • the retention time at the peak position is converted into the exclusion characteristics of the polysaccharide and PEG (polyethylene glycol) of the separation column used, the molecular weight of the terraced fulvic acid is about 4,000, and the molecular weight of the organic matter in the Humicle solution was estimated to be about 1,000 to 3,000.
  • the UV / TC value of the Humicle solution is almost similar to that of the Danto fulvic acid solution.
  • the similarity in ultraviolet absorption (220 nm) derived from the molecular structure of organic matter indicates that there is similarity in the skeleton and functional group types of both molecular structures.
  • FT-IR Fourier transform infrared spectrophotometer method
  • FIG. 1 shows an infrared absorption spectrum of fulvic acid contained in the humus extract (humicicle).
  • FIG. 2 shows infrared absorption spectra of fulvic acid and humic acid produced in Danto. Major infrared absorption peaks were extracted from FIG. 1 (Humicle) and FIG. 2 (Stepbo fulvic acid), and the results are shown in Table 3 in terms of wave number.
  • the fulvic acid contained in Humicle and the fulvic acid produced in Dando have a carboxyl group (C—O) absorption peak at 1200 cm ⁇ 1 in common, but the level of Humicle is higher than that of Danfu fulvic acid. small. That fulvic acid in Hyumikuru is clearly different spectrum of Danto producing fulvic acids are 1559,1047 and tri-substituted benzene type signals were observed at 835 cm -1, and phenol or an alcohol type 3362 and 1360 cm -1 Is observed. This suggests that the fulvic acid in Humicle has fewer carboxyl groups and more trisubstituted benzene type phenolic compounds than Danfu fulvic acid.
  • C—O carboxyl group
  • fulvic acid in Humicle has a skeleton and a functional group with a molecular structure peculiar to fulvic acid, similar to Danto fulvic acid. As shown in Examples and Comparative Examples described later, the fulvic acid in the humicle and the fulvic acid produced in the terrace have an effect of inhibiting MMP-1 production based on fulvic acid.
  • the ingestion method of the cosmetic composition of the present invention is percutaneous ingestion or oral ingestion. Therefore, the cosmetic composition of the present invention is processed into a form for oral administration such as a transdermal administration agent such as an emulsion or cream, or a solid preparation such as a tablet or a drop or a liquid such as a drink. From the viewpoint of a cosmetic composition for preventing photoaging, transdermal administration with a solution, emulsion, emulsion, cream or the like is preferred.
  • the cosmetic composition for transdermal administration of the present invention contains those commonly used as cosmetically, dermatologically and / or pharmaceutically acceptable additives.
  • water ethylene glycol, polyethylene glycol, propylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, dipropylene glycol, glycerin, diglycerin, polyglycerin, pentylene glycol, isoprene glycol, glucose, maltose, Polyhydric alcohols such as fructose, xylitol, sorbitol, maltotriose, erythritol; lower alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol, butyl alcohol, isobutyl alcohol; oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid Higher fatty acids such as acid, stearic acid, behenic acid, undec
  • the form of the cosmetic composition for transdermal administration of the present invention is a solution, solution, emulsion, emulsion, emulsion, cream, powder or solid. From the viewpoint of immediate effect for preventing photoaging, a form of liquid, liquid, emulsion, emulsion, emulsion, cream or powder is preferred.
  • the cosmetic composition for transdermal administration of the present invention includes cosmetics and bathing charges.
  • Specific uses include skin care cosmetics such as suntan cosmetics, cosmetic liquids, moisturizing lotions, soft skin lotions, and astringent lotions; body cosmetics such as farming cosmetics and anti-cellulite cosmetics; and basic cosmetics (skin lotions, emulsions, Creams), foundations, foundation creams, face powders, waterproofs, and other makeup cosmetics; soaps, shampoos, rinses, bathing agents such as bathing agents.
  • the content of the humus extract (containing about 3% fulvic acid) in the transdermal cosmetic composition of the present invention may be usually 0.01 to 20%, preferably 0.05 to 15%, more Preferably it is 0.1 to 10%.
  • the daily application amount of the transdermal cosmetic composition of the present invention may be usually 100 to 1,200 mg, preferably 300 to 1, as the application amount of the humic substance extract (containing about 3% fulvic acid). 200 mg, particularly preferably 300 to 600 mg.
  • the oral administration cosmetic composition of the present invention includes a functional food having a photoaging prevention function.
  • General-purpose food additives are added to the composition.
  • general-purpose excipients for example, depending on the form of oral administration, general-purpose excipients, disintegrants, binders, lubricants, vitamins, xanthine derivatives, amino acids, pH adjusters, cooling agents, suspending agents, thickeners, Solubilizing agents, antioxidants, coating agents, plasticizers, surfactants, water, alcohols, water-soluble polymers, sweeteners, corrigents, acidulants, fragrances, coloring agents, etc. It is possible to add in the target and quantitative range.
  • the form of the oral administration cosmetic composition of the present invention is processed into an oral administration agent different from ordinary foods such as powders, granules, capsules, pills, tablets, chewable tablets, drops, liquids or syrups. Is done.
  • the content of the humus extract (containing about 3% of fulvic acid) in the oral cosmetic composition of the present invention may be usually 0.1 to 70% by weight, preferably 0.1 to 30% by weight, More preferably, it is 0.1 to 15% by weight.
  • the daily intake of the oral cosmetic composition of the present invention may be usually 100 to 1,200 mg, preferably 300 to 1,200 mg as the intake of humus extract (containing about 3% fulvic acid). More preferably, it is 300 to 600 mg.
  • humus extract product name: Humicle, manufactured by Style and Value Japan Co., Ltd.
  • the cosmetic composition of the present invention was prepared by dissolving in an amount of 0.01% or 0.01% by weight.
  • humic standard substances obtained from the Japanese Society of Humic Substances, Danto fulvic acid (Comparative Example 1) and Lake Biwa fulvic acid (Comparative Example 2) were each dissolved in water at 0.1% by weight.
  • a cosmetic composition of a comparative example was prepared.
  • Retinoic acid is a derivative that facilitates the penetration of vitamin A into the skin. When taken into skin cells, it is reduced to retinol (vitamin A) by the enzyme. Retinoic acid activates the activity of skin cells to produce skin cells such as dermal collagen, and also has the effect of discharging melanin pigment to the skin surface, resulting in skin aging phenomena such as wrinkles and spots. It is known to have an improving effect. Therefore, as a positive control, a cosmetic composition was prepared by dissolving 1% of retinoic acid (manufactured by Wako Pure Chemical Industries, Ltd.) in water.
  • UV irradiation test of skin three-dimensional model A skin three-dimensional model (product name EPI-200, manufactured by Kurabo Industries Co., Ltd.), which has a structure similar to that of human skin and is an alternative to animal experiments such as cosmetics, was obtained. Pre-cultured for hours. At the top of this model, 100 ⁇ L of each sample was added and further cultured for 48 hours. Thereafter, the upper part of the model was washed with PBS ( ⁇ ).
  • UV wavelength 365 nm
  • the three-dimensional skin model after irradiation was cultured for 48 hours at a temperature of 37 ° C. in a CO 2 incubator. After culture, the amount of MMP-1 produced was measured by the MMP-assay described below, and the cell viability was measured by the MTT assay.
  • MMP-1 increased with an increase in UV irradiation dose, and conversely cell viability decreased.
  • 120 mJ / cm 2 at which the cell viability was about 70% was determined as the ultraviolet irradiation amount of the humic substance or retinoic acid addition test.
  • MMP-1 assay The culture supernatant after completion of the culture was collected and subjected to the MMP-1 assay.
  • the MMP-1 assay was performed using an ELISA kit (Funakoshi Co., Ltd.). Table 5 shows the amount of MMP-1 produced by each sample.
  • MTT-assay Cell viability measurement after UV irradiation
  • a three-dimensional skin model was subjected to MTT assay.
  • the MTT assay was performed by the following method. That is, after completion of the culture, an assay medium containing 1 mg / mL of MTT (3- (4,5-di-methylthiazol-2-yl) -2,5-diphenyltetrazole bromide, yellow tetrazole) (attached to the above skin model) ) was replaced with a medium containing 0.8 mL, and further cultured for 2 hours.
  • the skin model is transferred to a 24-well plate containing 2 mL of isopropanol, allowed to stand at 4 ° C. for 24 hours, and then left for 10 minutes on a shaker at 300 rpm, and then the formazan dye extracted in the isopropanol layer is removed. Photometry was performed at a wavelength of 540 nm. The cell viability was calculated with no test product added and no UVB irradiation as 100%. Table 5 shows the measurement results of cell viability.
  • the amount of MMP-1 produced in the non-irradiated test group was 5.11 ⁇ 0.39 ng / mL.
  • this non-added section was irradiated with ultraviolet rays, it increased to 20.17 ⁇ 0.32 ng / mL.
  • the test sections of Comparative Examples 1 and 2 fullvic acid concentration 0.1%) were irradiated with ultraviolet rays, MMP-1 was 15.77 ⁇ 3.85 ng / mL and 12.94 ⁇ 3.16 ng / mL, respectively. It became.
  • the production amount of MMP-1 was suppressed more than that in the non-added section.
  • the amount of MMP-1 produced in the test group of Example 1 was 13.94 ⁇ 0.97 ng / mL at a concentration of 0.1%, and 14.18 ⁇ 4.65 ng / mL at a concentration of 0.01%. Also in Example 1, the production amount of MMP-1 was suppressed more than that in the non-added section.
  • the cell viability decreased to 67.7 ⁇ 2.3% by ultraviolet irradiation.
  • the ratio was improved to 78.6% ⁇ 2.8%.
  • Comparative Examples 1 and 2 In the test groups of Comparative Examples 1 and 2, the cell survival rates were 65.1 ⁇ 6.1% and 69.4 ⁇ 7.1%, respectively, and no significant difference was observed compared to the non-added group. . In Comparative Examples 1 and 2, it is considered that UV reached the deep layer of the three-dimensional skin model and killed by the generated active oxygen. It has been found that the compositions of Comparative Examples 1 and 2 cannot improve the cell viability.
  • Example 1 the humus extract concentration was 95.9 ⁇ 5.9% at a concentration of 0.01% by weight, and 98.5 ⁇ 5.8% at a concentration of 0.1% by weight. A significant difference was observed. Compared with the positive control, the superior cell viability of Example 1 clearly shows that the cosmetic composition of the present invention is effective in preventing photoaging.
  • Example 1 has the same effect of suppressing MMP-1 production as Comparative Examples 1 and 2, the cell viability was different because the humus extract of Example 1 Compared with fulvic acid No. 2 and retinoic acid as a positive control, it is conceivable that the ultraviolet absorption is low and the ability to erase active oxygen generated by UVB is large. And this difference is considered that the structure of the humus extract of Example 1 contributes greatly.
  • the humus extract of Example 1 has less carboxyl groups than other fulvic acids, has many tri-substituted benzene type phenolic compounds, and does not have a naphthalene ring structure. Presumed to have led to a difference in performance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention vise à procurer une substance apte à inhiber la production de MMP-1 lors de l'irradiation par un rayonnement ultraviolet et également apte à améliorer un taux de survie cellulaire de manière à empêcher ainsi le vieillissement de la peau lié à la lumière de manière exhaustive ; et à fournir une utilisation de la substance. La présente invention décrit une composition cosmétique comprenant : un extrait d'humus qui comporte de l'acide fulvique et présente des pics d'absorption de rayon infrarouge aux nombres d'onde de 3362, 2875, 1675, 1559, 1360, 1200, 1047 et 835 cm-1 dans des spectres d'absorption de rayons infrarouges obtenus par un procédé FT-IR ; et un additif de qualité cosmétique acceptable, de qualité dermatologique acceptable et/ou de qualité pharmaceutique acceptable.
PCT/JP2017/009027 2016-03-08 2017-03-07 Composition cosmétique WO2017154912A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-044887 2016-03-08
JP2016044887A JP6120342B1 (ja) 2016-03-08 2016-03-08 美容組成物

Publications (1)

Publication Number Publication Date
WO2017154912A1 true WO2017154912A1 (fr) 2017-09-14

Family

ID=58666549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/009027 WO2017154912A1 (fr) 2016-03-08 2017-03-07 Composition cosmétique

Country Status (2)

Country Link
JP (1) JP6120342B1 (fr)
WO (1) WO2017154912A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113244156A (zh) * 2021-05-28 2021-08-13 广东省科学院化工研究所 一种抗衰老组合物及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3799854A1 (fr) * 2019-10-01 2021-04-07 Stefan Johannes Fellner Extrait de matériaux organiques humifiés
CN112190576A (zh) * 2020-10-19 2021-01-08 江苏集萃新型药物制剂技术研究所有限公司 皮肤外用制剂的组合物、皮肤外用制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526407A (ja) * 1998-10-08 2002-08-20 エナーコム（プロプライエタリー）・リミテッド フルボ酸、および種々の状態の処置におけるその使用
JP2006087393A (ja) * 2004-09-27 2006-04-06 Global Science:Kk 健康食品及び薬剤
JP2007308673A (ja) * 2006-05-22 2007-11-29 Masakazu Shirakawa ミネラル入り石鹸及びミネラル入り石鹸の製造法
JP4040077B1 (ja) * 2006-06-20 2008-01-30 株式会社ピュアハート 飲料水の製造方法及び装置
JP2012171937A (ja) * 2011-02-23 2012-09-10 Kose Corp 一重項酸素消去剤
JP2013107857A (ja) * 2011-11-22 2013-06-06 Funao Kurosawa 皮膚外用剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011063563A (ja) * 2009-09-18 2011-03-31 Fuji Chem Ind Co Ltd しわ改善組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002526407A (ja) * 1998-10-08 2002-08-20 エナーコム（プロプライエタリー）・リミテッド フルボ酸、および種々の状態の処置におけるその使用
JP2006087393A (ja) * 2004-09-27 2006-04-06 Global Science:Kk 健康食品及び薬剤
JP2007308673A (ja) * 2006-05-22 2007-11-29 Masakazu Shirakawa ミネラル入り石鹸及びミネラル入り石鹸の製造法
JP4040077B1 (ja) * 2006-06-20 2008-01-30 株式会社ピュアハート 飲料水の製造方法及び装置
JP2012171937A (ja) * 2011-02-23 2012-09-10 Kose Corp 一重項酸素消去剤
JP2013107857A (ja) * 2011-11-22 2013-06-06 Funao Kurosawa 皮膚外用剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113244156A (zh) * 2021-05-28 2021-08-13 广东省科学院化工研究所 一种抗衰老组合物及其应用

Also Published As

Publication number Publication date
JP2017160149A (ja) 2017-09-14
JP6120342B1 (ja) 2017-04-26

Similar Documents

Publication Publication Date Title
US20220218573A1 (en) Cosmetic compositions
US11992550B2 (en) Topical skin care formulations comprising plant extracts
KR102260986B1 (ko) 식물 추출물을 포함하는 국소 피부 케어 제형
KR102391369B1 (ko) 식물 추출물을 포함하는 국소 스킨 케어 제형
TW201206494A (en) Use of Tiliacora triandra in cosmetics and compositions thereof
KR20070030310A (ko) 홍경천을 포함하는 화장료 조성물 및 방법
WO2017154912A1 (fr) Composition cosmétique
KR20200064240A (ko) 초임계 유체 추출법을 이용한 괭생이모자반 추출물을 함유하는 항산화 또는 피부미백 화장료 조성물
JP2009067718A (ja) カエデ科植物樹液のフェノール性化合物を含有する皮膚外用剤
WO2018128104A1 (fr) Promoteur de la pousse des cheveux
JP2011020990A (ja) ホオノキ抽出物、その製造方法、およびそれを含む美肌組成物
JP2005029494A (ja) メラノサイト増殖抑制剤およびこれを含む化粧料
FR3051672A1 (fr) Composition cosmetique ou dermocasmetique comprenant un extrait de sureau et un derive organique de sillicium
KR101820732B1 (ko) 물푸레나무 추출물의 발효물을 포함하는 피부 미백용 조성물
JP7165293B2 (ja) 美容組成物
JP2004175767A (ja) 皮膚障害抑制剤、皮膚障害改善剤，及びそれらを含有する皮膚外用剤
JP2013129615A5 (fr)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17763252

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17763252

Country of ref document: EP

Kind code of ref document: A1